Greg has more than 25 years experience counseling senior management and has developed and executed strategic corporate communications programs for both publicly traded and private companies. Greg co-founded Richard Lewis Communications, Inc. in 1989 and spent 10 years building the business and rejoined the firm in June 2005. In May 2008, Greg became president & CEO.
Prior to re-joining the firm, Greg spent three years leading the healthcare practice as Executive Vice President at The Ruth Group where he built significant revenue for the life sciences group and counseled senior management on investor communications programs.
From 1999 to 2002, Greg was a Vice President at Morgen-Walke Associates, Inc. (now FTI Consulting) where he led multiple practice areas - healthcare and business services. Early in his career, Greg was Communications Manager for American Cyanamid's International Agricultural Division where he worked on a global basis with country managers in developing and building communications programs for animal health biologics and crop protection chemicals.
Greg actively participates in programs sponsored by the Biotechnology Industry Organization (BIO) and has developed speaker panels for the annual BIO CEO & Investor Conference in NYC. For many years he has reviewed applications and judged companies requesting presentation slots at the BIO Business Forum during the annual BIO International Convention.
Having developed strong relationships during his career with investment bankers, venture capitalist and journalists, Greg has counseled more than 50 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical device, diagnostics, healthcare services and financial services. He has a strong understanding of the stories reporters are seeking and works with clients to develop appropriate key messages to best convey the message that will resonate with multiple audiences including investors and potential partners.
Greg is a 1984 graduate of the University of Illinois at Urbana-Champaign.
Jason is responsible for guiding the firm's strategic direction as well as the day-to-day management of its clients' communications and public relations programs. From media visibility to product marketing to patient and physician education, Jason works with the TSAI team to design individualized communications programs that enable the firm's clients to direct their message to the audiences most integral to the growth of their business.
With more than 20 years industry experience, Jason has specialized in establishing and managing high-level communications programs for public and private companies in a number of industries, including healthcare (biotech, pharmaceutical, medical technology), financial services and technology. During Jason's career, his close ties with the top-tier national media have generated significant client exposure, including feature coverage in The Wall Street Journal, The New York Times, Bloomberg BusinessWeek, Dow Jones, Reuters, Forbes, Fortune, Investor's Business Daily, and more than 300 executive and financial analyst interviews on CNBC.
Prior to joining Tiberend Strategic Advisors, Jason spent nine years at The Ruth Group with increasing levels of responsibility, most recently as Senior Vice President, Public Relations and Healthcare Marketing.
Jason is a 1994 graduate of Tufts University with a degree in psychology.
Josh leads TSAI’s investor relations practice, drawing from an extensive background in the life sciences and years of experience working along side the Wall Street healthcare community. He specializes in translating complex science and high-level strategies into precise and straightforward corporate messages that resonate with investors. Along with the rest of the TSAI team, Josh offers key insights and diligent execution on investor targeting, collateral materials development, capital raises, financial reporting, and data communications.
Josh is also able to provide sound strategic counsel for emerging companies on competitive positioning of their R&D programs, products and technologies. In addition to broad technical mastery in microbiology, genetics, molecular biology, biochemistry, and animal disease modeling, Josh has professional experience communicating in a wide range of therapeutic areas, including oncology, pain and inflammation, infectious diseases, cardiovascular, immunology and autoimmunity, molecular diagnostics, medical devices, ophthalmology, CNS, drug delivery and genetic disorders.
Prior to joining Tiberend Strategic Advisors, Josh was Chief Scientific Counsel at The Ruth Group, where he helped lead the life sciences IR team and oversaw all scientific communications. Previously, Josh worked in healthcare investor relations at Burns McClellan, developing financial communications and strategic initiatives to raise visibility for both public and private life science companies.
Josh received an M.S. and Ph.D., both in microbiology and immunology, from the Albert Einstein College of Medicine of Yeshiva University in Bronx, New York.
Andrew specializes in developing client media strategy based on agreed parameters and key messages. He focuses on national business media as well as regional and local media.
Prior to joining Tiberend Strategic Advisors, Inc., Andrew was as an Account Executive at Rx Mosaic Health where he coordinated media campaigns for Sepracor's LUNESTA® and respiratory franchises. He additionally assisted in developing and executing media initiatives aimed at raising awareness among consumers, patients and physicians about Teva Neuroscience's COPAXONE® and Phase III oral laquinimod, which is a once-daily novel oral immunomodulatory agent developed as a disease modifying treatment for multiple sclerosis.
Some of Andrew's recent client story successes include articles in Forbes, Dow Jones Newswires, Thomson Reuters and Pharmawire. In addition, he has worked to generate clients' stories and management appearances on FOX, CNN, ABC, CBS, NBC and National Public Radio.
In order to provide the best client service and bring strategic ideas and opportunities to clients, Andrew continuously monitors news trends in the financial markets, healthcare and the political environment.
Andrew is a 2007 communications graduate of Seton Hall University.
Janine specializes in providing strategic communications counsel and tactical public relations advice that empower healthcare companies across the entire spectrum of development to build awareness and showcase their unique value proposition.
With more than 14 years of experience in public relations, Janine’s expertise runs the gamut of communications initiatives targeting investors, healthcare practitioners, consumers, employees and industry peers and regulators. She has managed communication strategies for clinical data, business development, crisis communications, product launches, executive changes and more. Her relationships have helped her to secure media coverage in national, business, and broadcast outlets as well as industry trade and regional publications.
For three years prior to joining Tiberend Strategic Advisors, Janine served as an Assistant Vice President at EVC Group where she secured media coverage primarily for small and mid-cap med-tech companies. Prior to EVC Group, Janine spent six years at The Ruth Group serving primarily bio-pharma clients with increasing levels of responsibility, most recently as Assistant Vice President.
Janine is a 2000 graduate of Oberlin College with a degree in Art History.
Jon specializes in translating complicated biomedical concepts into easily digestible information for investors. Drawing from his extensive scientific conference presentations, he excels at tailoring messages to targeted audiences with varied backgrounds.
Prior to joining Tiberend Strategic Advisors, Inc., Jon performed virology research at Robert Wood Johnson Medical School (RWJMS). Specifically, he worked on retroviral vectors used in clinical gene therapy, and published three scientific research articles in the Proceedings of the National Academy of Sciences and the Journal of Virology.
Jon received his Ph.D. in Biochemistry from the Graduate School of Biomedical Sciences at Rutgers University – RWJMS in Piscataway, New Jersey.